source
- Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent winA Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…
- Novartis-partnered Matchpoint Therapeutics raises $150 million Series B to fund clinical entryMatchpoint Therapeutics, a biotech company working with Novartis, announced the close of a new financing round. The round raised $150 million in Series B funding. The capital will be used to advan…